Catriona Yale Sells 614 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 614 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total value of $27,556.32. Following the completion of the sale, the insider now owns 95,034 shares in the company, valued at $4,265,125.92. This represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $49.87, for a total value of $498,700.00.
• On Monday, December 16th, Catriona Yale sold 9,074 shares of Akero Therapeutics stock. The shares were sold at an average price of $29.11, for a total value of $264,144.14.

Akero Therapeutics Stock Down 1.6 %

Shares of NASDAQ:AKRO opened at $44.15 on Friday. Akero Therapeutics, Inc. has a 52-week low of $17.86 and a 52-week high of $58.40. The stock has a market cap of $3.52 billion, a P/E ratio of -11.77 and a beta of -0.19. The business’s 50 day moving average is $42.10 and its 200 day moving average is $33.79. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Sell-side analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on AKRO. HC Wainwright upped their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, March 3rd. Canaccord Genuity Group increased their price target on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Citigroup increased their price target on Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Bank of America upgraded Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, UBS Group increased their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $76.29.

Institutional Trading of Akero Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. bought a new stake in Akero Therapeutics during the 4th quarter valued at $41,000. Sterling Capital Management LLC boosted its position in shares of Akero Therapeutics by 764.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock worth $50,000 after purchasing an additional 1,582 shares in the last quarter. Quarry LP acquired a new stake in shares of Akero Therapeutics in the 4th quarter worth $83,000. Summit Investment Advisors Inc. boosted its position in shares of Akero Therapeutics by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after purchasing an additional 450 shares in the last quarter. Finally, Summit Financial Wealth Advisors LLC acquired a new stake in shares of Akero Therapeutics in the 3rd quarter worth $205,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.